A Combined Pulmonary Function and Emphysema Score Prognostic Index for Staging in Chronic Obstructive Pulmonary Disease by Hopkinson, NS et al.
A Combined Pulmonary Function and Emphysema Score
Prognostic Index for Staging in Chronic Obstructive
Pulmonary Disease
Afroditi K. Boutou1, Arjun Nair1, Dariush Douraghi-Zadeh2, Ranbir Sandhu3, David M. Hansell1,
Athol U. Wells1, Michael I. Polkey1, Nicholas S. Hopkinson1*
1NIHR Respiratory Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, United Kingdom, 2Department of
Radiology, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom, 3Department of Radiology, Imperial College Healthcare NHS Trust, London, United
Kingdom
Abstract
Introduction: Chronic Obstructive Pulmonary Disease (COPD) is characterized by high morbidity and mortality. Lung
computed tomography parameters, individually or as part of a composite index, may provide more prognostic information
than pulmonary function tests alone.
Aim: To investigate the prognostic value of emphysema score and pulmonary artery measurements compared with lung
function parameters in COPD and construct a prognostic index using a contingent staging approach.
Material-Methods: Predictors of mortality were assessed in COPD outpatients whose lung computed tomography,
spirometry, lung volumes and gas transfer data were collected prospectively in a clinical database. Univariate and
multivariate Cox proportional hazard analysis models with bootstrap techniques were used.
Results: 169 patients were included (59.8% male, 61.1 years old; Forced Expiratory Volume in 1 second % predicted:
40.5619.2). 20.1% died; mean survival was 115.4 months. Age (HR= 1.098, 95% Cl = 1.04–1.252) and emphysema score
(HR= 1.034, 95% CI = 1.007–1.07) were the only independent predictors of mortality. Pulmonary artery dimensions were not
associated with survival. An emphysema score of 55% was chosen as the optimal threshold and 30% and 65% as
suboptimals. Where emphysema score was between 30% and 65% (intermediate risk) the optimal lung volume threshold, a
functional residual capacity of 210% predicted, was applied. This contingent staging approach separated patients with an
intermediate risk based on emphysema score alone into high risk (Functional Residual Capacity $210% predicted) or low
risk (Functional Residual Capacity ,210% predicted). This approach was more discriminatory for survival (HR = 3.123; 95%
CI = 1.094–10.412) than either individual component alone.
Conclusion: Although to an extent limited by the small sample size, this preliminary study indicates that the composite
Emphysema score-Functional Residual Capacity index might provide a better separation of high and low risk patients with
COPD, than other individual predictors alone.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common
condition and now the third leading cause of death worldwide [1].
The disease is heterogeneous, as a result of which survival rates in
published studies also vary [2] [3] and the prognostic accuracy of
both pulmonary [4] [5] [6] and extrapulmonary [7] [8] [9]
features have been investigated. It has also been suggested that
multidimensional indices may wield more prognostic information
than any of these parameters alone [10] [11]. However, no index
has evaluated any quantification measure of the disease severity in
terms of imaging, although this approach has been proven to
accurately stage patients in terms of prognosis in other respiratory
disorders [12].
Computed tomography (CT) is widely used for the diagnosis,
characterization and quantification of emphysema in COPD
patients in secondary care [13]. However, data on the impact of
these parameters on survival in COPD remain limited [14] [15]
[16] [17] and no direct comparison has been made in terms of
prognosis between a full range of lung function measurements and
imaging. CT has also been used to evaluate pulmonary artery
enlargement; the pulmonary artery to ascending aorta ratio
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(PA:Ao) has been previously found to be a strong predictor of
pulmonary hypertension in patients with various respiratory
disorders [18]. Moreover, a PA:Ao ratio .1 has recently been
reported to be an independent predictor of severe exacerbations
among COPD patients [19]. However, it is not known whether
pulmonary artery dimensions are a prognostic indicator in COPD.
Using a single continuous parameter such as a CT emphysema
score or a lung function parameter to predict outcome would be
most useful for extreme values and least useful around the cut-off
point where a small change may move an individual from a
‘‘good’’ to a ‘‘bad’’ prognostic group. We propose an approach
where for individuals in the intermediate risk group a second
parameter is used to determine prognosis; a contingent staging
approach.
We have previously demonstrated that carbon monoxide gas
transfer factor (DLco) is the lung function measure most strongly
associated with survival in COPD [5]. Therefore, we conducted a
preliminary study in order: a) to investigate the prognostic power
of CT derived parameters of emphysema score and pattern as well
as pulmonary artery enlargement in COPD and b) secondly to
compare their prognostic power to gas transfer and other lung
function measurements. Finally, we investigated whether an
approach to survival prediction based on contingent probability
in COPD could be developed.
Materials and Methods
Ethics Statement
The Royal Brompton, Harefield and NHLI Research Ethics
Committee has stated that ethical approval is not required for the
retrospective analysis of routinely collected clinical data. Specific
consent was therefore not obtained but data were anonymised for
this analysis.
Study population
Clinical data of COPD patients attending a hospital clinic were
entered prospectively into a database as reported previously [5].
Data for patients who had a high resolution CT (HRCT) of the
thorax available between March 1999 and April 2011, together
with full lung function testing were extracted. Patients with
medical history of chronic heart failure (New York Heart
Association III or IV), chronic renal failure, peripheral vascular
disease or malignancy were excluded from the analysis. The
Charlson comorbidity index (CCI) [20] was calculated to adjust
for the rest of comorbidities. Patients were treated with b2-
agonists, anticholinergics and inhaled corticosteroids in various
combinations, consistent with clinical guidelines. Exacerbations
were clinically defined by the worsening of respiratory symptoms,
requiring treatment with antibiotics and/or oral steroids. The
number of exacerbations in the previous year was a priori
categorized as 0–1/year, 2–4/year and .4/year. Vital status on
1st April 2013 was determined from the UK National Health
Service Central database and survival was calculated from the date
of the CT.
Study measurements
HRCT acquisition and interpretation. Imaging had been
performed using an electron-beam CT (Imatron Inc., San
Francisco, CA, USA), 4-slice multidetector CT (Volume Zoom,
Siemens, Erlangen, Germany), or 64-slice CT (Somatom Sensa-
tion 64, Siemens, Erlangen, Germany). Images were either
acquired at 10-mm intervals (electron-beam and 4-slice CT) or
using a volumetric acquisition (64-slice CT) in a supine position
from the lung apices to the bases at full inspiration. Images were
reconstructed at thin section width (1.0 mm to 1.5 mm) using a
high spatial resolution algorithm and reviewed on a workstation at
appropriate window settings for viewing the lung parenchyma
(window centre =2500 HU; window width = 1500 HU).
Two radiologists (R.S. and D.D.Z.), blinded to the patients’
clinical details, independently reviewed the CT scans and
calculated the average emphysema score (ES) within a range of
0–100. In order to calculate the ES, which was the visual
assessment of the percentage of lung volume with low attenuation
areas (,2950 HU), a subjective estimation was made to the
nearest 5% for each lobe [right upper lobe (RUL), right middle
lobe (RML), right lower lobe (RLL), left upper lobe (LUL), left
lower lobe (LLL) and lingula, which was treated as a separate
lobe]. The six scores which were obtained from every observer for
each patient they were then averaged in order to calculate the total
ES (as a percentage). A consensus score was reached between the
two observers in all cases where one lobe’s ES was zero according
to one observer and more than a zero according to the other.
Heterogeneous emphysema was defined by the presence of a
difference in average ES greater than 25% between the best and
the worst lobe (that is between the lobe with the minimum and the
lobe with the maximum average emphysema score) [21]. Among
patients with heterogeneous emphysema, the ratio of the extent of
emphysema in both upper lobes (RUL, RML, LUL and lingula) to
that in both lower lobes (RLL and LLL) was calculated and
designated as U/L ratio [22]. Patients with a U/L ratio of 1.0 or
more were determined to have predominantly upper-lobe disease
and those with a U/L ratio of less than 1.0, predominantly lower-
lobe disease, according to a previous published technique [22].
Additionally, one observer (R.S.) also measured the CT vascular
parameters of interest, namely: a) the diameter of the main PA at
the level of the bifurcation [23], b) the ratio of PA diameter at the
level of its bifurcation to the diameter of the ascending aorta in its
maximum dimension (PAAo ratio) [24], c) the diameter of the
main PA at the level of the right main PA [24], and d) the axial
diameters of the right and left main Pas [23]. Measurements of the
PA dimensions were made with electronic calipers on the
workstations.
Pulmonary Function Testing. A CompactLab System
(Jaeger, Hoechberg, Germany) was utilized to conduct spirometry,
gas transfer and lung volumes measurements by body plethys-
mography. Device calibrations and quality control were done
according to published guidelines [25]; lung volumes were
calibrated prior each patient test, gas analyzer calibrations for
gas transfer measurement were done prior each session and
biological calibrations were conducted daily. Arterialized capillary
blood samples were used to measure arterial blood gases; this
technique is carried out routinely by clinical physiologists in our
hospital and it has similar results, while better tolerated compared
to the traditional radial artery blood sampling [26]. For lung
function parameters, the European Coal and Steel Community
predicted values were used [25] and the values of carbon
monoxide diffusion capacity (DLco) and transfer coefficient
(Kco) were adjusted for haemoglobin concentration, according
to previously published equations [27]. Pulmonary function testing
(PFT) values closest to the thorax CT scan and within a 12-month
interval were used.
Statistical analysis
Statistical analysis was performed using the Predictive Analytics
Software (PASW, SPSS Inc) version 18. The Shapiro-Wilk
normality test was applied and data are presented as mean
value61 standard deviation (SD) or as median (range). Inter-
observer variability for ES measurements was tested using the
COPD Prognosis - Emphysema Score and Lung Volumes
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intraclass correlation coefficient. Group comparisons were made
using t-test, Mann-Whitney U test, Chi-squared or Fisher exact
test as appropriate. To determine optimal and suboptimal ES
thresholds, several ES values were tested against mortality, using
univariate proportional hazards analysis and comparing the area
under curve (AUC) in ROC analysis; a similar technique was
engaged to identify best PFT predictor. All parameters univari-
ately associated with survival entered a proportional hazard
multivariate Cox regression model to identify independent
predictors of mortality. A forward stepwise selection method with
entry testing based on the significance of the score statistic, and
removal testing based on the probability of the Wald statistic was
used. The p-values for entry and removal from the multivariate
model were 0.05 and 0.1, respectively. The proportionality hazard
(PH) assumption was tested for every variable of the final model,
using the partial residual plots (Schoenberg residuals PH test) and
was fulfilled for all independent predictors of mortality. Boot-
strapping was utilized both in univariate and multivariate survival
analysis and Hazard Ratios (HR) are reported with corresponding
bias-corrected 95% Confidence Intervals (95% CIs). The number
of random samples obtained during bootstrapping was 1000.
Results
Study population
169 patients (59.8% male, 61.7 years old) with COPD who were
followed up for a mean period of 115 months constituted the study
population (Table 1). At the time of enrolment 4.9% of patients
were stage I by GOLD classification,[28] 16.6% stage II, 32.5%
stage III and 46% stage IV. The median age-unadjusted Charlson
comorbidity index (CCI) for the study population was 1 and
98.2% of patients presented with CCI#2. Thirteen percent of
patients were on long-term oxygen treatment. The intraclass
correlation coefficient between the two observers for emphysema
score was 0.734 (0.649–0.800) and for 19 patients a consensus
emphysema score had to be reached.
Predictors of mortality
During the follow up period 20.1% (n = 34) patients died. Mean
survival was 115.1 months (95% CI = 101.3–128.8). Surviving
patients were younger, had a lower CT emphysema score, less
airflow obstruction, less hyperinflation and better gas transfer. Sex,
Body Mass Index, pack-years, arterial blood gases and exacerba-
tion rate were similar between the two groups as was emphysema
heterogeneity and distribution, PA:Ao ratio and PA, RPA, LPA,
and Ao diameters (Table 2). All parameters which were
univariately associated with survival (Table 3) were entered in a
stepwise multivariate Cox proportional hazard model (as described
in the methods section). This identified that age (HR = 1.098, 95%
Cl = 1.04–1.252) and ES (HR = 1.034, 95% CI = 1.007–1.07) were
the only independent predictors of mortality (Table S1).
Emphysema Score thresholds
In univariate survival analysis ES was a strong, independent
predictor of mortality and its prognostic value was tested using
several threshold values from 20 to 70 (Table 4). Although several
cut-off values were significantly associated with mortality, the 55%
was selected as optimal. The 55% cut-off separated the population
in two subgroups: a smaller one with ES$55% (N1 = 64; 37.9%)
with a mean survival of 94.6 (71.8–117.4) months, and a larger one
with ES,55% (N2 = 105; 62.1%) and a mean survival of 116
(103.9–128.1) months (p = 0.003) (Figure 1A). In patients with
ES,55% mortality was not associated with ES (HR = 1.029; 95%
CI = 0.992–1.097), while in patients with ES$55% there was a
definite association between ES and mortality (HR = 1.097; 95%
CI = 1.003–1.228). Compared to the other three thresholds which
separated the patient population in a similar manner (that is the
45%, the 50% and the 60% threshold) the 55% cut-off point also
had the highest AUC when it was evaluated by the ROC curve
method (Figure S1).
In order to classify patients further, ES scores of 30% and 65%
were identified as suboptimal thresholds, applying a similar
method. The use of both suboptimal threshold values overall
separated the population in three subgroups: subgroup A with
ES,30% (N1 = 40; 23.7%), subgroup B with ES$65% (N2 = 33;
19.5%) and subgroup C or ‘‘intermediate’’ with 30%#ES,65%
(NC = 96; 56.8%). In the univariate mortality analysis, subgroup B
presented with significantly higher mortality risk (HR = 8.228;
95% CI = 2.489–27.199) compared to subgroup A. As expected,
no difference was noted in mortality risk (HR = 2.672; 95%
CI = 0.910–7.848) of the ‘‘intermediate’’ subgroup C (Figure 1B).
Pulmonary Function Testing threshold values
Univariate Cox proportional hazard analysis (Table 3) indicat-
ed that Functional Residual Capacity (FRC) % predicted, Kco %
predicted and Residual Volume (RV) % predicted were the three
PFT parameters which carried the most prognostic information
for COPD patients. Several thresholds of FRC % predicted, Kco
% predicted and RV % predicted were tested against mortality.
The range of threshold values tested was chosen based on each
variable’s mean and standard deviation with incremental increases
of 5%. Although FEV1% predicted was not found to be such a
strong predictor of mortality in the univariate analysis, it is an
every-day measurement, feasible in most clinical settings, so
several thresholds of this parameter were also tested against
mortality. The results of the univariate Cox proportional hazard
analysis for all PFT parameters are presented in Tables S2–S5.
The PFT chosen as optimal was FRC % predicted. Its threshold
values of 185%, 195% and 210% were of similar prognostic value,
according to the univariate proportional hazard survival analysis.
However the 210% threshold had the highest AUC, and was
chosen as optimal threshold for FRC % predicted (Table S2)
(Figure S2). When the FRC cut-off value was used, 15.4% (n = 26)
of patients presented with FRC % predicted $210%, while the
rest 84.6% (n = 143) had FRC % predicted ,210%. On
proportional hazards analysis the FRC % predicted threshold of
210% was significantly associated with mortality (HR = 4.122;
95% CI = 1.900–8.012) and separated the patient population in
two subgroups: the one below cut-off value with mean survival of
121.6 (107.3–135.8) months and the one above cut-off value with
mean survival of 58.4 (45.3–71.6) months (p =,0.001). However,
when FRC % predicted was entered in the multivariate Cox
proportional Hazard analysis as a categorical variable, ES and age
were still the only independent predictors of mortality.
A clinical algorithm for prognostic staging
Based on the above, a clinical algorithm (ES-FRC index) was
constructed. According to the ES-FRC index, patients in subgroup
B (ES$65%) were categorized as ‘‘high risk’’ and patients in
subgroup A (ES,30%) were categorized as ‘‘low risk’’ patients.
Patients in subgroup C (30%#ES,65%) with FRC % predicted
$210% were also characterized as ‘‘high risk’’, while the ones with
FRC % predicted ,210% were grouped in the ‘‘low risk’’
category (Figure 2).
The use of ES-FRC index offered significant prognostic
information (HR = 4.215; 95% CI = 1.99–8.466) and the distinc-
tion between ‘‘high risk’’ and ‘‘low risk’’ patients was much more
discriminatory than the use of ES 55% threshold or the ES
COPD Prognosis - Emphysema Score and Lung Volumes
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subthresholds and slightly more discriminatory than the FRC
210% predicted threshold value alone (Figure 1A–D). Mean
survival for ‘‘low risk’’ patients was 128 (114.1–142.6) months
and for ‘‘high risk’’ patients was 63.7 (54.5–72.9; p,0.001)
months. When ES-FRC index was entered along with age, Forced
Expiratory Volume in 1 second (FEV1) % predicted, FEV1/
Forced Vital Capacity ratio (FEV1/FVC), Kco % predicted, RV
% predicted, Total Lung Capacity (TLC) % predicted, Inspiratory
Capacity/TLC ratio (IC/TLC) and RV/TLC in the multivariate
proportional hazard analysis model, it remained the only
independent predictor of mortality (HR = 3.123; 95%
CI = 1.094–10.412 along with age (HR = 1.105; 95%
CI = 1.040–1.221) (Table S6).
To further confirm the accuracy of the ES-FRC index,
alternative indices using the other two potentially ‘‘optimal’’
FRC thresholds of 185% and 195% were constructed. The use of
the combined ES-FRC185 index was a predictor of mortality in the
univariate Cox proportional hazard analysis (HR = 3.749; 95%
CIs = 1.927–10.0845) but not in the multivariate analysis
(HR = 2.337; 95% CIs = 0.773–8.568). Likewise, the ES-FRC195
index was univariately associated with mortality (HR = 4.248; 95%
CIs = 2.106–10.085) but could not offer any prognostic informa-
tion in the multivariate model (HR = 2.678; 95% CIs = 0.554–
10.454). Due to the feasibility of FEV1 measurement a potential
ES-FEV1 index was also tested, using the ‘‘optimal’’ FEV1
threshold of 30% predicted. Although ES-FEV1 index was
associated with mortality in the univariate analysis (HR = 2.404;
95% CIs = 1.284–5.129) it was far less discriminatory than any
other ES-FRC index and it could not independently predict
mortality in the multivariate Cox proportional hazard model
(HR = 2.491; 95% CI = 0.786–10.507).
Discussion
This preliminary study indicates that visual, HRCT-derived ES
along with age is a predictor of all-cause mortality in a cohort of
Table 1. Characteristics of the study population.
Age (years) 61.769.9
Sex, male (%) 59.8
BMI (kg/m2) 24.967.7
Charlson comorbidity index 1 (3)
Average Emphysema Score (%) 45.3619.6
Emphysema Distribution (%)
N Homogenous 29
N Heterogenous 71
PA:Ao Ratio (%)
N #1 92.1
N .1 7.9
Main pulmonary artery diameter (mm) 26.564.1
Ascending aorta diameter (mm) 3364
Left pulmonary artery diameter (mm) 19.363.7
Right pulmonary artery diameter (mm) 19.7610
FEV1 (% predicted) 39.5619
FVC (% predicted) 99.3639.9
FEV1/FVC 34.5612.7
TLC (% predicted) 124.5619.7
RV (% predicted) 195.4660.1
IC/TLC (%) 28.569.3
RV/TLC (%) 56.6611.7
FRC % predicted 170639.4
DLco (% predicted) 41.7617
Kco (% predicted) 78.2632.4
PaO2 (kPa) 9.361.3
PaCO2 (kPa) 5.260.8
Pack–years smoked 42.9621.8
Exacerbations (%)
N 0–1/year 31.9
N 2–4/year 44.4
N .4/year 23.7
BMI: Body Mass Index; PA:Ao; Pulmonary artery to Ascending Aorta Ratio, FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; TLC: Total Lung
Capacity; FRC: Functional Residual Capacity; RV: Residual Volume; IC: Inspiratory Capacity; DLco; Carbon Monoxide Diffusion Capacity; Kco; Carbon Monoxide Diffusion
coefficient, PaO2: arterial Oxygen Partial Pressure; PaCO2: arterial Carbon Dioxide Partial Pressure.
doi:10.1371/journal.pone.0111109.t001
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stable COPD outpatients. The prognostic value of ES alone was
higher than all other lung function parameter tested and in
multivariate analysis including ES no lung function parameter was
retained. Although results from multivariate analysis should be
treated with caution, due to the small sample size, this study
indicated that a prognostic algorithm which separated patients in
‘‘high’’ and ‘‘low’’ risk, based on the combination of ES and FRC
% predicted thresholds carried more prognostic information than
individual predictors. A second notable finding was the absence of
prognostic impact associated with pulmonary artery parameters
and with the degree or pattern of emphysema heterogeneity.
Significance of the findings
Although HRCT is increasingly used among patients with
COPD, published data on the association between ES and
mortality are few and limited by the fact that they refer to selected
patient populations. The prognostic impact of ES has been
identified among patients with early-stage lung cancer [29],
among patients with alpha-1 antitrypsin deficiency [17] and in a
population of individuals who were undergoing screening for lung
cancer [14]. Haruna et al identified an association between ES and
mortality among COPD patients; however the patient population
was predominantly male (approximately 94%) [16], so the results
cannot be easily generalized in other COPD populations. On the
contrary, Martinez et al did not identify a relation between ES and
mortality among COPD patients randomized to the medical arm
of the NETT study [2]; however, this was a patient population
recruited specifically to have severe emphysema so the spectrum of
disease necessary to identify a prognostic factor would have been
absent. In the very recent study of Johannessen et al [15], the
Table 2. Differences between survivors and non-survivors at baseline.
Survivors (n =135) Non-survivors (n=34) p
Age (years) 60.9610 64.868.8 0.042
Gender (%)
N Male 81.2 18.8 NS
N Female 77.9 22.1
BMI (kg/m2) 24.965.6 24.8613.1 NS
Charlson comorbidity index 1(3) 1(1) NS
Average Emphysema score (%) 43.3619.5 53.2618.3 0.008
Emphysema distribution (%)
N Homogenous 75.5 24.5 NS
N Heterogenous 81.7 18.3
Emphysema predominance (%)
N Upper 83.8 16.2 NS
N Lower 81.8 18.2
PA:Ao ratio
N #1 83.5 16.5 NS
N .1 75 25
FEV1% predicted 41.2619.8 32.8614.1 0.006
FVC % predicted 101.4633.4 90.8659 NS
FEV1/FVC 35.6613.3 30.168.7 0.004
TLC % predicted 122.9619.9 130.7618.1 0.04
RV % predicted 190659.7 216657.5 0.019
IC/TLC (%) 29.869.4 23.467.8 0.001
RV/TLC (%) 55.1611.6 62.2610.7 0.002
FRC % predicted 165.5638.7 187.5637.8 0.003
DLco % predicted 42.9616.1 36.8619.4 0.02
Kco % predicted 40.6631.9 68.8631.9 0.049
PaO2 (kPa) 9.461.3 89.161.4 NS
PaCO2 (kPa) 5.160.8 5.360.9 NS
Pack-years 42.7621.4 48.6623.3 NS
Exacerbations (%)
N 0–1/year 81.4 18.6
N 2–4/year 80 20 NS
N .4/year 81.3 18.8
BMI: Body Mass Index; PA:Ao; Pulmonary artery to Ascending Aorta Ratio, FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; TLC: Total Lung
Capacity; FRC: Functional Residual Capacity; RV: Residual Volume; IC: Inspiratory Capacity; DLco; Carbon Monoxide Diffusion Capacity; Kco; Carbon Monoxide Diffusion
coefficient, PaO2: arterial Oxygen Partial Pressure; PaCO2: arterial Carbon Dioxide Partial Pressure.
doi:10.1371/journal.pone.0111109.t002
COPD Prognosis - Emphysema Score and Lung Volumes
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111109
prognostic value of ES was confirmed in a large community
population of ever-smokers, half of whom had COPD, but the
only lung function test evaluated was FEV1 % predicted. Thus,
this preliminary study is the first one to indicate that ES is a
predictor of mortality in a general COPD outpatient population of
varying severity and that it carries significantly higher prognostic
information when compared to spirometric values, lung volume
measurements and gas transfer parameters alone.
COPD is a highly heterogeneous disease, characterized by a
range of physiological impairments and structural abnormalities
which cannot be adequately assessed using a single measurement
[30]. Thus, multidimensional systems, such as the BODE [31], the
ADO [11] and the DOSE index [32] have been proposed for
COPD staging. Although their prognostic impact and discrimina-
tive properties versus several individual components have been
previously indicated [33] [34], there are some limitations
regarding their construction and use. None of these indices has
included any CT parameter, although imaging can define the
complex pathophysiological changes occurring within the lung
better than clinical symptoms or airflow obstruction do [30].
Moreover, for the construction of those indexes no optimal
selection of the best PFT measure took place, but the FEV1 %
predicted was arbitrarily selected as a measure of airflow
obstruction, although the latter is not the only or best lung
function determinant of survival [5] [35]. Our study is the first one
to use ES and FRC % predicted thresholds for the construction of
a prognostic algorithm after several imaging variables, lung
function parameters and demographic characteristics were com-
pared to each other in terms of prognostic accuracy.
Table 3. Mortality, expressed as Hazard Ratios with bias-corrected 95% confidence intervals for baseline data.
Parameter HR 95% CI p
Age (years) 1.052 1.016–1.1 0.009
Gender (%)
N Male 1.209 0.626–2.351 0.557
N Female reference
BMI (kg/m2) 0.992 0.866–1.029 0.889
Charlson comorbidity index 0.404 0.101–1.618 0.200
Average Emphysema score (%) 1.037 1.015–1.070 0.001
Emphysema distribution (%)
N Homogenous 0.738 0.537–2.29 0.746
N Heterogenous reference
Emphysema predominance (%)
N Lower 0.753 0.383–1.602 0.397
N Upper
PA:Ao ratio
N .1 0.753 0.366–1.643 0.423
N .1 reference
FEV1% predicted 0.974 0.951–1.008 0.016
FVC % predicted 0.752 0.990–1.007 0.511
FEV1/FVC 0.963 0.933–0.985 0.009
TLC % predicted 1.031 1.008–1.058 0.008
RV % predicted 1.010 1.003–1.017 0.001
RV/TLC 1.070 1.038–1.105 0.002
IC/TLC 0.02 0.01–0.04 0.009
DLco % predicted 0.970 0.943–0.989 0.009
Kco % predicted 0.970 0.955–0.984 0.001
FRC % predicted 1.020 1.010–1.031 0.001
PaO2 (kPa) 0.855 0.685–1.132 0.198
PaCO2 (kPa) 1.339 0.845–2.142 0.207
Pack-years 1.003 0.976–1.031 0.810
Exacerbations (%)
N .4/year 1.225 0.424–3.536 0.708
N 2–4/year 1.259 0.511–3.100 0.617
N 0–1/year reference
BMI: Body Mass Index; PA:Ao; Pulmonary artery to Ascending Aorta Ratio, FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; TLC: Total Lung
Capacity; FRC: Functional Residual Capacity; RV: Residual Volume; IC: Inspiratory Capacity; DLco; Carbon Monoxide Diffusion Capacity; Kco; Carbon Monoxide Diffusion
coefficient, PaO2: arterial Oxygen Partial Pressure; PaCO2: arterial Carbon Dioxide Partial Pressure.
doi:10.1371/journal.pone.0111109.t003
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Several studies have previously investigated the impact of
pulmonary function parameters on mortality among COPD
patients. Lung hyperinflation indices have been previously shown
to have an impact on COPD survival, both in a general COPD
population [6] and among patients with type II respiratory failure
[36]. In a previous study of our group [5] measures of airflow
Table 4. Mortality expressed as Hazard Ratios with corresponding bias-corrected 95% confidence intervals for several ES
thresholds.
ES threshold* HR 95% CI p
20 3.252 0.777–13.610 0.106
25 2.964 0.904–9.721 0.073
30 3.361 1.178–9.589 0.023
35 2.404 1.041–5.552 0.040
40 2.538 1.153–8.232 0.012
45 2.829 1.332–7.941 0.004
50 2.744 1.271–7.170 0.004
55 2.787 1.496–2.351 0.001
60 2.314 1.060–5.280 0.011
65 4.306 2.171–9.679 0.001
70 4.258 1.952–16.610 0.002
ES: emphysema score.
*The category with the lower score is used as reference.
doi:10.1371/journal.pone.0111109.t004
Figure 1. Kaplan Meier curves for the COPD population, categorized according to A) ES optimal threshold of 55%, B) ES
subthresholds of 30 and 65%, C) FRC % predicted optimal threshold of 210% and D) ES-FRC composite index.
doi:10.1371/journal.pone.0111109.g001
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obstruction, lung hyperinflation and gas transfer were compared in
terms of prognostic significance. Although all three categories were
univariately associated with mortality, only DLco % predicted
remained an independent predictor of mortality in the multivar-
iate analysis; however ES was not analyzed in that study. These
previous results are consistent with rather than contradicting the
present ones; DLco reflects lung parenchymal destruction and loss
of capillary bed and is thus highly correlated with emphysematous
changes in CT [37]. Lung parenchymal destruction thus appears
to be the most important determinant of COPD mortality,
followed possibly by hyperinflation indices which further increase
the mortality risk. The present data suggest that CT quantification
of emphysema is probably a more useful marker than gas transfer
measurements which may be relevant where a choice of measures
is being made, for example in the context of designing intervention
trials where mortality is an outcome measure.
The use of this contingent staging approach allows a more
accurate and plausible prognostic categorization of the patient
population. The ES is the parameter which is best correlated to
mortality (apart from age); however, in clinical terms no variable
could be 100% accurate in defining prognosis by the use of a single
threshold. One could hypothesize that while mild COPD may not
significantly affect mortality among patients with other comorbid-
ities [38], the impact of the disease becomes major among those
with severe lung destruction. Thus, after defining the ES
subthresholds of ‘‘mild’’ and ‘‘severe’’ disease, the choice of a
second predictor offers further prognostic information. Since FRC
is not an every-day measurement which could be conducted
outside hospital settings, an attempt to construct an index
incorporating FEV1 % predicted was also made (Table S4).
However, the FEV1 optimal threshold of 30% predicted was not
independently associated with mortality, indicating that the
severity of obstruction is probably not as discriminatory as
hyperinflation is, in terms of prognosis.
Although average ES was a strong predictor of mortality, the
other CT parameters which were tested did not carry any
prognostic information. A PA:Ao ratio .1 has been previously
shown to be associated with increased risk of severe exacerbations
in a large COPD cohort [19]. Our patient population had more
severe obstruction, so it may be that the prognostic value of the
index differs in patients with more severe disease. No association
with mortality was evident, even when the PA:Ao index and the
pulmonary artery and ascending aorta diameters were treated as
continuous variables. Emphysema distribution was another CT-
defined index which was not associated with survival prediction;
neither homogeneous versus heterogeneous, nor upper-lobe versus
lower-lobe predominant emphysema, predicted mortality. Marti-
nez et al found that patients with lower-zone compared to upper-
zone predominant emphysema had a higher risk of dying.
However, these were patients with severe COPD randomized in
the medical arm of NETT [2], so results are quite difficult to
compare.
Critique of methods
The study’s small sample size and the lack of external validation
are the most important limitations. The use of bootstrapping
procedure has contributed to the internal validity of the study,
although the number of candidate predictors is still quite high in
Figure 2. COPD prognostic staging in high and low risk, according to the ES-FRC composite index.
doi:10.1371/journal.pone.0111109.g002
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relation to the number of events, so model ‘‘overfitting’’ cannot be
altogether excluded. Thus, results of multiple testing should be
interpreted with some caution. However, this is a hypothesis-
generating study describing the contingent staging approach for
constructing a prognostic algorithm in a COPD population, so
results are to be confirmed with larger, prospective studies in the
future.
A strength of the study is that data were collected prospectively
into a clinical audit database and thus the study population reflects
an unselected clinical population. CT scanning was performed as
part of routine clinical work-up, and not only in a patient subset
being selected for a specific intervention, so indication bias is
unlikely. However, we studied secondary care patients who are
likely to have emphysema predominance, so conclusions should be
extrapolated with some caution in primary care patients with
milder disease and less emphysema. Data on hospitalizations due
to exacerbation were not systematically collected, nor were the
MRC dyspnea score and exercise capacity, so the composite
BODE index, a known predictor of mortality [31], could not be
calculated and compared to the ES-FRC index in terms of
prognostic accuracy. All scans and lung function measurements
were conducted in the same center, minimizing the effect of
different techniques and devices seen in multicenter studies.
Survival data, being extracted from the UK National Health
Service central dataset, were accurate although specific cause of
death could not be determined.
In conclusion, we have conducted a hypothesis generating
study, where we proposed a scoring system based on CT imaging
and lung volumes for the prognostic staging of COPD patients into
‘‘high’’ and ‘‘low’’ risk, utilizing a contingent staging approach.
The 30% and 65% thresholds of ES and the 210% threshold of
FRC % predicted carried more prognostic information than ES
and PFTs individually. More studies are needed in larger
populations in order for this index to be validated in clinical
practice and to be compared to other multidimensional indices.
However, this study provides an argument that CT and full lung
function measurements should be routinely considered, including
in a clinical trial setting or other interventions, where COPD
mortality is the outcome of interest.
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